CLINICAL TRIAL

CURETINA

Retinal RED

Observational

Early Phase 1

CURETINA personalized medicine in hereditary retinal degenerations

Rare Eye Disease concerned by the trial :
Hereditary retinal degenerations caused by mutations in genes CRB1, CRX, PROM1

Status of the trial : completed

Orphan drug recognition : N/A

Inclusion criteria : Retinal degeneration caused by mutations in either of the genes CRB1, CRX, PROM1

Exclusion criteria : Additional mutations in genes known for causing hereditary retinal degenerations; additional eye diseases influencing the retinal morphology and function (glaucoma, retinal detachment, etc.)

Inclusion opening date : 01/02/2016

Inclusion closing date : 30/06/2018

Children ☑

Adults ☑

Within ERN-EYE members

Principal location of the trial :

Center for Ophthalmology, University of Tübingen
Elfriede-Aulhorn-Str. 7
72076 Tübingen
Germany

Contact details



Principal investigator name :
Katarina Stingl

Other investigators :
Laura Kühlewein

Center for Ophthalmology, University of Tübingen
Tübingen, Germany

Funder type : National institution